Is Compounded Semaglutide Legal in 2026?

Compounded semaglutide is a version of the active ingredient in Ozempic® and Wegovy® prepared by a licensed compounding pharmacy rather than by the drug's manufacturer. It is not an FDA-approved drug product, and its legal status changed substantially between 2025 and 2026.

This page is for anyone currently taking a compounded GLP-1, considering one, or trying to work out whether the provider they found online is operating inside federal law. It is also for clinicians and clinic operators who need the current compliance position rather than a headline.

Below you'll find the exact legal test the FDA applies, the dates that changed the rules, what remains permitted right now, the state-level layer most coverage skips entirely, and a checklist for verifying any source before you inject anything.

The Short Answer

Compounded semaglutide is not banned in the United States, but it is no longer broadly legal. Since the FDA declared the semaglutide shortage resolved on February 21, 2025, compounding a copy of Ozempic or Wegovy is only permitted in narrow, patient-specific circumstances that a prescriber must document individually. Compounding it because it is cheaper is not one of them.

That is the whole answer in one paragraph. The rest of this page explains where the line sits, because the line is where almost everyone gets this wrong — in both directions.

Why This Question Gets Two Opposite Answers Online

Search this topic and you will find pages insisting compounded semaglutide has been banned outright, and pages insisting it "remains legal and available in all 50 states." Both are selling something.

Neither is accurate, because compounding legality is not a property of the drug. It is a property of the transaction — who compounded it, under which section of federal law, for which named patient, with what documentation. The same vial of compounded semaglutide can be lawful for one patient and unlawful for the next.

Here's what that means in practice: when you ask "is compounded semaglutide legal," the honest answer is a question back — legal under what circumstances, for whom, prescribed by whom, and documented how?

What Compounded Semaglutide Is — And What It Is Not

Drug compounding is the practice of a licensed pharmacist preparing a medication tailored to an individual patient. It exists for real clinical reasons: a liquid formulation for a patient who cannot swallow tablets, a dye-free version for someone with a documented allergy, a strength that no manufacturer produces.

Compounded semaglutide products are not FDA-approved. The FDA has not reviewed them for safety, effectiveness, or manufacturing quality before they reach a patient, and they are not generic equivalents of Ozempic or Wegovy. A generic drug must demonstrate bioequivalence to an approved reference product and receive FDA approval. A compounded preparation does neither.

This distinction is not academic. Between September 2025 and June 2026 the FDA issued more than 55 warning letters to telehealth companies, and the most frequently cited violation was marketing language implying a compounded product was the same as, or equivalent to, an FDA-approved GLP-1 (U.S. Food and Drug Administration [FDA], 2026a). Claims as simple as "same active ingredient as Wegovy and Ozempic" were cited as misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act.

If a website tells you its compounded product is "the same as" a brand GLP-1, that sentence is itself a regulatory violation — and a useful signal about the rest of the operation.

How Compounded Semaglutide Became Legal in the First Place

Two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) govern compounding, and they work differently.

Section 503A covers state-licensed pharmacies and physicians compounding for an individual patient based on a valid prescription. A 503A pharmacy may not compound — regularly or in inordinate amounts — a drug that is "essentially a copy" of a commercially available product.

Section 503B covers outsourcing facilities: FDA-registered operations that produce large batches under current Good Manufacturing Practice, often without patient-specific prescriptions. A 503B facility generally cannot compound from a bulk drug substance unless that substance appears on the 503B Bulks List or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing (FDA, 2026b).

Semaglutide entered the FDA shortage list in 2022. That listing is what opened the door: when a drug is in shortage, the "essentially a copy" restriction relaxes, and 503B facilities gain a bulk-compounding pathway. An entire industry — telehealth subscriptions at roughly $150 to $300 a month against four-figure branded list prices — was built inside that door.

The door was never permanent. It was tied to the shortage, and the shortage ended.

The FDA Timeline: Every Date That Changed the Rules

Sources: FDA (2026b); Federal Register (2026); Sheppard Mullin (2026).

What Is Still Legal Right Now (August 2026)

The surviving pathway is Section 503A patient-specific compounding, and it is narrower than most telehealth marketing implies.

A state-licensed pharmacy may still compound semaglutide for a named patient where the prescriber has determined and documented that the compounded preparation contains a change producing a significant difference from the commercially available product for that identified individual patient (FDA, 2026b).

The FDA has also stated it does not currently intend to act against a compounder for producing an essentially-a-copy product "regularly or in inordinate amounts" if that compounder fills four or fewer prescriptions of that product in a calendar month (FDA, 2026b). That threshold is worth reading twice. It is the practical ceiling of what enforcement discretion covers — and it is incompatible with any subscription model serving thousands of patients.

What can qualify as a significant difference

• A documented allergy or intolerance to an inactive ingredient in the commercial product

• A strength or concentration the approved product does not offer, where the prescriber documents why that patient needs it

• A dosage form the patient genuinely cannot use, with the clinical reason recorded in the chart

What does not qualify

• Cost. The FDA has explicitly declined to treat affordability or insurance denial as a clinical need.

• Convenience or preference.

• Adding vitamin B12 alone. The FDA has stated it may treat a semaglutide-plus-B12 combination as essentially a copy where the route of administration matches and the strengths are within 10% of the respective commercial products (FDA, 2026b). Regulators have signalled that a trivial addition does not survive the test.

• A supply backorder. The agency has said supply issues are not what "clinical need" means, because shortage compounding already has its own separate pathway.

The documentation is the thing that makes it legal. Not the pharmacy's license, not the API certificate, not the words on the website. If no prescriber wrote down a patient-specific clinical reason, the exemption does not attach.

What Is No Longer Legal

• Compounding standard-dose injectable semaglutide as a routine, lower-cost substitute for Ozempic or Wegovy

• 503B bulk compounding of semaglutide from bulk drug substance, since it sits on neither the Bulks List nor the shortage list

• Marketing a compounded product as identical, equivalent, or comparable to an FDA-approved GLP-1

• Compounding from salt forms such as semaglutide sodium or semaglutide acetate; these are treated as different active ingredients, and multiple state boards prohibit them outright

• Compounding investigational molecules such as retatrutide and cagrilintide, which have no approved reference product

One nuance that matters for anyone comparing GLP-1s: liraglutide has been in a different position from semaglutide and tirzepatide, having remained on the FDA shortage list at points during 2026 — which can permit 503B compounding even while it is absent from the Bulks List (Epstein Becker Green, 2026). Shortage status changes without notice. Verify the current listing in the FDA Drug Shortages Database before relying on it.

The 503B Bulks List Proposal: What Happens Next

On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, stating it had not identified sufficient evidence of a clinical need for outsourcing facilities to compound them from bulk drug substances (FDA, 2026c).

If finalized as written, this would close the 503B bulk pathway permanently — meaning these substances could not be bulk-compounded by outsourcing facilities even if a future shortage were declared.

The comment period ran from May 1 to July 30, 2026, after a 30-day extension. Thousands of comments were filed. As of August 21, 2026, the FDA has not announced a final determination.

Two points for anyone currently on a compounded GLP-1:

1. This proposal does not change 503A rules. Patient-specific compounding by state-licensed pharmacies operates under a separate statutory provision and is not directly affected.

2. A proposal is not a rule. Nothing about your current prescription changed on July 30. But the direction of travel has been consistent for eighteen months, and building a long-term treatment plan around a narrowing exemption is a risk worth naming out loud.

The State Layer Most Articles Skip

Federal law sets a floor, not a ceiling. A state board of pharmacy cannot relax federal requirements, but it can add to them — and the difference between states is largely about enforcement appetite, not written rules (Sheppard Mullin, 2026).

Only California has enacted a GLP-1-relevant rule carrying the force of law. Everything else in the "stricter" column is board guidance or an AG posture — which shapes enforcement without being a promulgated regulation.

Practical translation: the pharmacy filling your prescription may be perfectly compliant in Texas and exposed in California or Ohio. If you have moved states, or your telehealth provider ships across state lines, that is worth asking about directly.

Is It Legal for You to Have It?

This is the question people actually want answered, and almost nobody addresses it.

Federal compounding law regulates compounders, prescribers and distributors — not patients. The FD&C Act provisions discussed above impose obligations on pharmacies and outsourcing facilities. A patient who received a compounded medication through a licensed prescriber and a licensed pharmacy is not the target of that framework.

Two things change the picture:

• Importing GLP-1s from overseas sellers is a different legal question entirely, and one where the FDA maintains import alerts on GLP-1 active pharmaceutical ingredients with quality concerns. Personal importation of unapproved drugs is not a safe harbor.

• Buying "research use only" peptides and self-administering them is not compounding, not a prescription, and not covered by any of the exemptions above. RUO material is explicitly not intended for human use.

The realistic risk to a patient is not prosecution. It is receiving a product with unverified potency, sterility or purity — and having no recourse when something goes wrong.

Can You Still Get Compounded Semaglutide?

Yes, in narrower circumstances than in 2024 — and the way you obtain it now determines whether it is lawful.

What a compliant 503A pathway looks like:

• A licensed US prescriber evaluates you and documents a specific clinical reason the commercial product does not meet your needs

• A state-licensed pharmacy, licensed in your state, fills that individual prescription

• The active ingredient is the semaglutide base — not a salt form — from an FDA-registered source with a certificate of analysis

• The volume is consistent with patient-specific compounding, not batch production

• Nothing in the marketing claims equivalence to an approved drug

What is not compliant, regardless of how the website is worded: a two-minute questionnaire with no clinician contact, a flat monthly subscription with no individualized clinical justification, a pharmacy that won't tell you its name and license number, or any seller shipping from outside the United States.

A 2025–2026 audit that submitted standardized requests to 49 GLP-1 websites found that 91.8% issued a prescription and 69.4% shipped the medication, with a median time to prescription of one day or less — and two compounded orders approved in five minutes or less (American Journal of Managed Care, 2026). Speed is not a feature here. It is a measure of how little clinical review took place.

What the Safety Data Actually Shows

The regulatory tightening did not happen in a vacuum.

• As of May 21, 2026, the FDA had received more than 1,700 adverse event reports associated with compounded semaglutide and tirzepatide (FDA, 2026a).

• A recurring pattern in those reports is dosing errors — patients drawing doses from multidose vials at home, without the prefilled pen mechanism that makes brand products harder to over-administer. Some required hospitalization.

• In litigation, Novo Nordisk has alleged that its own testing of certain compounded injectable semaglutide products found impurities as high as 86% — a claim made in court filings rather than an independent finding, and one the defendants dispute.

• A 2026 study found that when tirzepatide is compounded with vitamin B12, the two substances can chemically bond to form a molecule not present in the approved drug; the clinical consequences are unknown (Stanford Medicine, 2026).

Adverse event reports are not confirmed causal findings, and the number should be read against a very large denominator. But the pattern — dosing errors, sourcing uncertainty, untested combination formulations — is consistent enough that the American Diabetes Association and the American Medical Association have both cautioned against compounded GLP-1 use where approved products are available.

Who Should Not Use Semaglutide

Semaglutide is not appropriate for everyone, and this applies to compounded and FDA-approved products alike. Only a licensed clinician can determine suitability after a full history.

Contraindicated:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Known hypersensitivity to semaglutide or any component of the formulation

• Pregnancy, attempting pregnancy, or breastfeeding. Semaglutide is not recommended during pregnancy, and current labeling advises discontinuing well in advance of a planned pregnancy. This is stated explicitly because it is frequently omitted.

Requires careful clinical assessment before use:

• History of pancreatitis

• Gastroparesis or severe gastrointestinal disease

• Diabetic retinopathy, particularly in type 2 diabetes

• Severe renal impairment, or dehydration risk from persistent vomiting or diarrhoea

• History of an eating disorder

• Gallbladder disease

• Concurrent use of another GLP-1 receptor agonist, which is not recommended

• Concurrent insulin or sulfonylurea therapy, due to hypoglycaemia risk requiring dose adjustment

Additional considerations specific to compounded products: because compounded preparations are not FDA-approved, they may differ from approved products in concentration, excipients, sterility assurance and storage requirements. Any known sensitivity to preservatives or delivery agents should be raised with your prescriber before the first dose.

Seek immediate medical attention for severe or persistent abdominal pain radiating to the back, persistent vomiting, signs of an allergic reaction, or any neck lump, hoarseness or difficulty swallowing.

Legal Alternatives and What They Cost in 2026

The economics that drove the compounded market have shifted materially. Every option below is an FDA-approved product available through normal pharmacy channels.

Prices verified August 2026 from manufacturer programmes. GLP-1 pricing has changed several times in the past twelve months — confirm current figures at novocare.com and lillydirect.com before budgeting.

Two things worth knowing: generic semaglutide is not expected in the United States before the early 2030s due to patent protection, and efficacy differs across these options — cross-trial comparisons put mean weight loss at roughly 14.9% for injectable semaglutide, 20.9% for tirzepatide, and 11–12% for orforglipron over 68–72 weeks in their respective pivotal trials. These are trial averages under study conditions, not predictions for any individual.

Seven Questions to Ask Before Your Next Refill

Save this. Ask them in writing, and keep the reply.

1. Which pharmacy compounds my medication, and what is its license number and state? A provider that will not name the pharmacy is the answer.

2. Is it a 503A pharmacy or a 503B outsourcing facility? This determines which legal framework applies to your prescription.

3. Is that pharmacy licensed in my state? Cross-state shipping without the right licensure is a live enforcement issue.

4. What is the documented, patient-specific clinical reason my prescription is compounded rather than an approved product? If nobody can point to it in your chart, the exemption may not apply.

5. Is the active ingredient semaglutide base, and can I see the certificate of analysis? Salt forms are not appropriate for compounding.

6. Who is the prescribing clinician, what is their license, and how do I reach them about a side effect?

7. What happens to my treatment if the FDA finalizes the 503B Bulks List exclusion? A provider with a real answer has thought about continuity of care.

Frequently Asked Questions

Did the FDA ban compounded semaglutide?

No. There is no FDA document banning compounded semaglutide. What happened is that the FDA declared the shortage resolved in February 2025, which removed the legal basis for compounding copies of Ozempic and Wegovy. Narrow patient-specific compounding under Section 503A remains permitted when a prescriber documents an individual clinical need.

Is compounded semaglutide legal in all 50 states?

Not in the same way everywhere. Federal law sets a uniform floor, but California has codified stricter requirements, and states such as Ohio and Washington enforce aggressively. Some states pursue enforcement through consumer-protection law rather than pharmacy regulation. Ask your provider which state licensure applies to your prescription.

Can I get in legal trouble for taking compounded semaglutide? 

Federal compounding law places obligations on pharmacies, prescribers and distributors rather than patients. The realistic risk to a patient is a product of unverified quality, not prosecution. Importing GLP-1s from overseas sellers or using "research use only" peptides is a separate and riskier situation.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded preparations are not FDA-approved and have not been reviewed for safety, effectiveness or manufacturing quality. They are not generics. The FDA has issued warning letters specifically over marketing language implying equivalence.

Why is compounded semaglutide cheaper?

Compounded preparations do not carry the cost of clinical trials, FDA review or branded manufacturing and distribution. They also do not carry the associated regulatory oversight. As of 2026 the price gap has narrowed considerably, with several approved options available between roughly $149 and $449 per month through manufacturer self-pay programmes.

What happens if the FDA finalizes the 503B Bulks List exclusion?

Outsourcing facilities would be barred from bulk-compounding semaglutide, tirzepatide and liraglutide from bulk drug substances — permanently, and regardless of any future shortage. Patient-specific 503A compounding would not be directly affected. As of August 21, 2026 the proposal remains pending with no final determination announced.

Could the semaglutide shortage come back and reopen compounding?

It is possible in principle. If a drug returns to the FDA shortage list, the compounding exemptions tied to that listing can reactivate. However, if the current 503B Bulks List proposal is finalized as written, the 503B bulk pathway would be closed for these substances even during a future shortage.

How do I switch from compounded semaglutide to an approved product?

Speak to your prescriber before changing anything. Dose conversion is not always one-to-one, and stopping abruptly can bring back appetite signalling quickly. Your clinician can map your current dose to an approved product's titration schedule and identify which manufacturer programme fits your situation.

Medical Disclaimer

The information on this page is provided for educational purposes only and does not constitute medical or legal advice. Regulatory information is current as of August 31, 2026 and this area of federal and state law changes frequently. Individual results may vary. Please consult a qualified medical practitioner before starting, stopping or changing any medication to determine what is appropriate for your specific health condition, and consult a licensed attorney for legal questions about compounding compliance.

Talk to a Licensed Provider

If you are currently taking a compounded GLP-1 and are unsure where your prescription sits, the useful next step is a conversation with a licensed clinician who can review your history, your documented clinical need, and the FDA-approved options now available to you.

Check your eligibility with a licensed US physician at Zynox RX

Compounded medications are not FDA-approved as finished drug products and are not equivalent to Ozempic®, Wegovy®, Mounjaro® or Zepbound®. Only a licensed physician can determine whether any treatment is appropriate for you.

References

American Journal of Managed Care. (2026). Online GLP-1 sellers often skip clinician oversight. https://www.ajmc.com/view/online-glp-1-sellers-often-skip-clinician-oversight

Epstein Becker Green. (2026, May 6). FDA proposal would leave semaglutide, tirzepatide, and liraglutide off 503B bulks list. Health Law Advisor. https://www.healthlawadvisor.com/fda-proposal-would-leave-semaglutide-tirzepatide-and-liraglutide-off-503b-bulks-list

Federal Register. (2026, May 1). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act, 91 Fed. Reg. 23431. https://www.federalregister.gov/documents/2026/05/01/2026-08552/

Sheppard, Mullin, Richter & Hampton LLP. (2026, August 6). Above the federal floor: How states are regulating compounded GLP-1s and peptides. https://www.sheppard.com/insights/blogs/above-the-federal-floor-how-states-are-regulating-compounded-glp-1s-and-peptides

Stanford Medicine. (2026, July). Compounded GLP-1s: Why doctors worry and the FDA is cracking down. https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html

U.S. Food and Drug Administration. (2026a). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

U.S. Food and Drug Administration. (2026b, April 1). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

U.S. Food and Drug Administration. (2026c, April 30). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list